Dare Bioscience, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Dare is a women’s-health biopharmaceutical company whose operations are primarily research and development. XACIATO is FDA-approved and licensed to Organon; the remaining portfolio consists of candidates at clinical and preclinical stages.
Financial results and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $10.0 million | $0 | $10.0 million |
| Operating expenses | $9.0 million | $9.6 million | $17.4 million | $18.0 million |
| Operating income (loss) | $(9.0) million | $0.4 million | $(17.4) million | $(8.0) million |
| Net income (loss) | $(8.8) million | $0.4 million | $(16.8) million | $(8.0) million |
| Operating cash flow | Not presented separately | Not presented separately | $(22.7) million | $(20.8) million |
- No revenue was recognized in 2023 through June. The prior-year $10.0 million was the one-time XACIATO license fee recognized when the Organon agreement became effective.
- Q2 research and development expense declined 11% year over year to $6.0 million; general and administrative expense rose 5% to $2.9 million. For the first half, R&D declined 12% to $11.1 million while G&A rose 17% to $6.3 million.
- At June 30, cash and cash equivalents were $13.3 million, total assets $23.2 million, current liabilities $24.7 million, total liabilities $25.9 million, and stockholders’ deficit $2.7 million. Working capital deficit was approximately $2.5 million.
- Cash, cash equivalents and restricted cash declined by $21.0 million in the first half. Financing provided $1.8 million, primarily from ATM share sales and warrant exercises. Cash and cash equivalents were $34.7 million at December 31, 2022.
- The filing reports no conventional borrowing outstanding at June 30; lease liabilities totaled approximately $0.3 million. Deferred grant funding liabilities of $13.7 million are grant funds not yet applied to eligible expenses, rather than ordinary borrowing. Substantially all cash at quarter-end related to grants restricted to program costs, with about 10% available for supported overhead and administration.
Changes, outlook and material developments
- Liquidity and going concern: Management says available cash is insufficient for working capital and other liquidity needs over the 12 months following issuance of the statements, and identifies substantial doubt about the company’s ability to continue as a going concern. It says additional capital is needed to fund operations into Q4 2023. If funding is unavailable, programs could be delayed, reduced or discontinued, or the company could reorganize, file for bankruptcy or cease operations.
- Funding and spending: Management expects significant losses and negative operating cash flow to continue. It expects 2023 R&D expense to be below 2022, citing cost savings, and says spending priorities include Ovaprene, Sildenafil Cream and other development programs. Cost controls may affect timelines for DARE-HRT1, DARE-VVA1 and DARE-204/214. Grant funds support DARE-LARC1 and DARE-LBT but are largely limited to those programs.
- XACIATO: The first U.S. commercial sale was expected in 2023. In July, Organon paid $1.0 million under a license amendment for FDA fees, manufacturing costs and continued advancement of the product; the company expects to recognize it as Q3 2023 license revenue. The amended terms provide a $1.8 million payment following first U.S. commercial sale. Dare is also eligible for tiered double-digit royalties and up to $180.0 million in regulatory and commercial milestones. The filing says first-year royalties were not expected to materially affect cash resources.
- Clinical programs: In the Sildenafil Cream Phase 2b RESPOND study, neither co-primary endpoint achieved statistical significance at study end. Some secondary and exploratory measures showed differences from placebo at selected time points; the company reported the product was generally well tolerated and plans to determine a Phase 3 design after further analyses and FDA discussions. Ovaprene Phase 3 enrollment was targeted to begin in Q4 2023, subject to study execution and funding. The company said DARE-204/214 Phase 1 studies and DARE-FRT1/DARE-PTB1 clinical starts were not expected in 2023.
- Capital and dilution: The company sold 454,592 shares under its ATM program in the first half for approximately $0.45 million net. It sold an additional 1,151,578 shares in July and August for approximately $0.95 million gross. Shares outstanding were 87,785,166 as of August 9, 2023.
- Nasdaq listing: Nasdaq notified the company in July that its share price had remained below the $1.00 minimum bid requirement; the initial compliance period ran to January 16, 2024. The company also reported negative stockholders’ equity at June 30 and said it expected a separate notice regarding Nasdaq’s equity and other continued-listing standards. Compliance and potential delisting were not assured.
- Other unusual items: First-half G&A included a one-time business-email-compromise fraud loss of approximately $230,000, net of insurance proceeds. Subsequent to quarter-end, the company financed about $0.8 million of insurance premiums at approximately 8% annual interest, payable through April 2024. It also reported a July NICHD grant award of approximately $385,000 for preclinical work.
Most important facts for investors to verify
- Whether the company secures sufficient, usable capital to meet near-term obligations and address the disclosed going-concern uncertainty.
- Whether XACIATO launches as expected, and the timing and terms of any resulting milestone, supply and royalty receipts under the amended Organon agreement.
- How management and the FDA interpret the RESPOND results, including the Phase 3 design, endpoints, budget and development decision for Sildenafil Cream.
- Whether Ovaprene Phase 3 enrollment begins on schedule and whether the existing CRADA funding covers the study’s costs.
- Progress toward Nasdaq bid-price and financial listing compliance, including any further notices or proposed remedies.
- The pace of ATM issuance and other financing, resulting dilution, and whether grant-restricted cash is sufficient for the programs it is intended to support.